David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared Bernie Bochner’s post on X, adding:
“Congrats to Bernie Bochner, Juan C Osorio, Ali Ghasemzadeh, Paul Bunyan Rosenberg, Eugene Pietzak, Memorial Sloan Kettering Cancer Center, UrologyMSK, on exciting translational science now out in Clinical Cancer Research.
Intravesical CD40 agonism for BCG-unresponsive NMIBC: 40% CR, median DOR 20 months.
Spatial immune organization may predict response and guide future bladder-sparing immunotherapy combinations – trials on-going now.”
Our team @MSKCancerCenter @RockefellerUniv are excited to see our completed #bladderCA trial using intravesical anti-CD40 targeting in press. Ongoing anti-CD40 PH3 trial for NMIBC opened!
Bernie Bochner, Urologic Surgeon, Oncology Researcher at Memorial Sloan Kettering Cancer Center (MSK), shared:
“Our team Memorial Sloan Kettering Cancer Center, Rockefeller University are excited to see our completed bladder cancer trial using intravesical anti-CD40 targeting in press. Ongoing anti-CD40 PH3 trial for NMIBC opened!”
Title: Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial
Authors: Juan C. Osorio, Lucas Blanchard, Ning Yao, Syed M. Alam, Ali Ghasemzadeh, Steven Grudman, Karissa Whiting, Venkatraman E. Seshan, Andrew Mijacika, Carlo Sevilla, Juan C. Angulo-Lozano, Ved P. Sharma, Morgan Tomberlin, Melissa McCarter, Jessica Pfau, Jeffrey L. Wong, David A. Knorr, Timothy F. Donahue, Robert Smith, Eugene J. Pietzak, Benjamin Greenbaum, Hikmat Al-Ahmadie, Jonathan E. Rosenberg, Jeffrey V. Ravetch, Bernard Bochner
You can also read:
